...
首页> 外文期刊>International journal of urology: official journal of the Japanese Urological Association >Renal transplantation after myeloablative and non-myeloablative hematopoietic cell transplantation from the same donor.
【24h】

Renal transplantation after myeloablative and non-myeloablative hematopoietic cell transplantation from the same donor.

机译:来自同一供体的清髓性和非清髓性造血细胞移植后的肾移植。

获取原文
获取原文并翻译 | 示例
           

摘要

Hematopoietic cell transplantation is a key treatment to prolong patient survival for many hematological disorders. Renal impairment is well recognized as a significant complication of hematopoietic cell transplantation, which can progress to end-stage renal disease. Herein, we report our experience of two patients who underwent renal transplantation from the same donor who provided cells for the preceding hematopoietic cell transplantation. One patient had undergone peripheral blood stem cell transplantation with a non-myeloablative conditioning regimen, whereas the other had received bone marrow transplantation with a myeloablative regimen. Chronic immunosuppressive therapy was not needed in either one to maintain the kidney graft function. Not only bone marrow transplantation with a myeloablative conditioning regimen, but also peripheral blood stem cell transplantation with a non-myeloablative regimen can confer immunological tolerance.
机译:造血细胞移植是延长许多血液系统疾病患者生存率的关键治疗方法。公认的肾脏损害是造血细胞移植的重要并发症,可发展为终末期肾脏疾病。在此,我们报告了两名患者的经验,这些患者来自同一供者的肾脏移植,该供者为先前的造血细胞移植提供了细胞。一名患者接受了非清髓性调理方案的外周血干细胞移植,而另一名患者接受了清髓性方案的骨髓移植。任何一种都不需要长期免疫抑制疗法来维持肾移植功能。不仅骨髓移植采用清髓疗法的方案,而且外周血干细胞移植与清髓疗法的方案都可以赋予免疫耐受性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号